Append Medical develops a transcatheter Left Atrial Appendage closure system that utilizes a proprietary vacuum mechanism to invert and ligate LAA tissue without implanting any devices in the heart. This approach significantly reduces the risks of device-related thromboembolism and peri-device leakage, addressing the heightened stroke risk faced by patients with non-valvular atrial fibrillation.
Funding
$13.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with non-valvular atrial fibrillation face a significantly increased risk of stroke. Current Left Atrial Appendage (LAA) occlusion solutions carry inherent risks of device-related thromboembolism (DRT) and peri-device leakage (PDL), both of which elevate the risk of stroke.
Solution
Append Medical is developing the Appligator, a transcatheter system for LAA closure that utilizes a vacuum mechanism to invert and ligate LAA tissue without leaving any foreign material or implants in the heart. This approach aims to eliminate the risks of DRT and PDL associated with existing LAA occlusion devices. The Appligator is designed to universally fit a wide range of anatomies, offering a solution that is both safe and effective.
Target Audience
The primary target audience includes interventional cardiologists and electrophysiologists treating patients with non-valvular atrial fibrillation who are at risk of stroke and require LAA occlusion.
Features
- Transcatheter delivery system for minimally invasive LAA closure
- Proprietary vacuum-based mechanism for LAA tissue inversion and ligation
- No implantable device left in the heart, eliminating DRT risk
- Ligation-based closure to prevent PDL
- Designed to accommodate a wide range of LAA anatomies